JP2005523687A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005523687A5 JP2005523687A5 JP2003557507A JP2003557507A JP2005523687A5 JP 2005523687 A5 JP2005523687 A5 JP 2005523687A5 JP 2003557507 A JP2003557507 A JP 2003557507A JP 2003557507 A JP2003557507 A JP 2003557507A JP 2005523687 A5 JP2005523687 A5 JP 2005523687A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- tm7xn1
- moiety
- compound
- astrocytoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100010882 ADGRG1 Human genes 0.000 claims 9
- 101710005049 ADGRG1 Proteins 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 208000003174 Brain Neoplasms Diseases 0.000 claims 7
- 102000004965 antibodies Human genes 0.000 claims 7
- 108090001123 antibodies Proteins 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 7
- 206010003571 Astrocytoma Diseases 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 238000003384 imaging method Methods 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 208000009956 Adenocarcinoma Diseases 0.000 claims 4
- 206010025650 Malignant melanoma Diseases 0.000 claims 4
- 206010038389 Renal cancer Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 201000010982 kidney cancer Diseases 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- 208000005017 Glioblastoma Diseases 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 108091007172 antigens Proteins 0.000 claims 3
- 102000038129 antigens Human genes 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 230000001472 cytotoxic Effects 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 238000007913 intrathecal administration Methods 0.000 claims 2
- 210000004443 Dendritic Cells Anatomy 0.000 claims 1
- 108020004999 Messenger RNA Proteins 0.000 claims 1
- 238000010171 animal model Methods 0.000 claims 1
- 210000004027 cells Anatomy 0.000 claims 1
- 230000001413 cellular Effects 0.000 claims 1
- 230000002604 chemotoxic Effects 0.000 claims 1
- 231100000196 chemotoxic Toxicity 0.000 claims 1
- 230000000875 corresponding Effects 0.000 claims 1
- 230000003828 downregulation Effects 0.000 claims 1
- 230000002708 enhancing Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 229920002106 messenger RNA Polymers 0.000 claims 1
- 230000000051 modifying Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000002285 radioactive Effects 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
- 108020003112 toxins Proteins 0.000 claims 1
- 210000004881 tumor cells Anatomy 0.000 claims 1
- 230000003827 upregulation Effects 0.000 claims 1
Claims (27)
- 脳腫瘍、腺癌、非黒色腫癌、及び腎臓癌からなる群より選択される腫瘍の診断又は病期決定のための方法であって、TM7XN1の発現の上方制御又は下方制御を決定することを含む、方法。
- 脳腫瘍が星状細胞腫である、請求項1記載の方法。
- 星状細胞腫が神経膠芽腫である、請求項2記載の方法。
- 決定が、脳腫瘍細胞内のmRNA又はポリペプチドの量の増加又は減少を検出することを含む、請求項1記載の方法。
- 脳腫瘍、腺癌、非黒色腫癌、及び腎臓癌からなる群より選択される腫瘍の画像化の方法であって、
イメージング部分と結合している、TM7XN1タンパク質と特異的に結合する化合物を、有効量、患者へ投与すること;及び
前記複合体のイメージング部分を可視化することを含む、方法。 - 複合体がクモ膜下腔内投与によって投与される、請求項5の方法。
- 化合物が血管内投与によって投与される、請求項5の方法。
- 腫瘍が星状細胞腫である、請求項5の方法。
- 星状細胞腫が神経膠芽腫である、請求項8の方法。
- 化合物が抗体又は抗体断片である、請求項5の方法。
- イメージング部分が、X線撮影用部分、陽電子放射部分、光学的に可視の色素、光学的に可視の粒子、及び磁気スピンコントラスト部分からなる群より選択される、請求項5の方法。
- 脳腫瘍、腺癌、非黒色腫癌、及び腎臓癌からなる群より選択される腫瘍を処置する方法であって、1個または複数の細胞毒性部分と結合している、TM7XN1タンパク質と特異的に結合する化合物を、治療的な量、投与することを含む、方法。
- 化合物がクモ膜下腔内投与によって投与される、請求項12の方法。
- 化合物が血管内投与によって投与される、請求項12の方法。
- 腫瘍が星状細胞腫である、請求項12の方法。
- 星状細胞腫が神経膠芽腫である、請求項15の方法。
- 化合物が抗体又は抗体断片である、請求項12の方法。
- 抗体がヒト抗体である、請求項17記載の方法。
- 抗体がTM7XN1の細胞外ドメインと特異的に結合するものである、請求項17記載の方法。
- 細胞毒性部分が、放射性部分、化学毒性部分、及び毒素タンパク質部分からなる群より選択される、請求項12の方法。
- 脳腫瘍、腺癌、非黒色腫癌、及び腎臓癌からなる群より選択される腫瘍に対する免疫応答を増強するための方法であって、
TM7XN1ポリペプチドの抗原を含む免疫原性組成物を宿主へ投与することを含む、方法。 - 宿主が脳腫瘍に罹患している、請求項21記載の方法。
- 投与工程が、単離された樹状細胞を抗原と共にインキュベートすることをさらに含む、請求項21の方法。
- 抗原がサイトカインと融合している、請求項21の方法。
- 腫瘍タンパク質標的遺伝子又は遺伝子産物の活性を調整する生物学的活性薬剤を開発するための方法であって、
候補の生物学的活性薬剤を、
(a)TM7XN1ポリペプチド;
(b)TM7XN1ポリペプチドをコードし発現する核酸を含む細胞;又は
(c)(i)TM7XN1に対応する遺伝子のノックアウト;(ii)TM7XN1をコードする外因性の安定的に伝達された哺乳動物遺伝子配列のうちの一つを含む、腫瘍遺伝子機能のための非ヒトトランスジェニック動物モデルのうちのいずれか一つと組み合わせること;並びに
腫瘍により誘導された分子及び細胞の変化に対する前記薬剤の効果を決定することを含む、方法。 - 生物学的活性薬剤が、発現を下方制御又は上方制御するものである、請求項25記載の方法。
- 生物学的活性薬剤が、ポリペプチドの活性を阻害するか又は増加させるものである、請求項25記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34342201P | 2001-12-27 | 2001-12-27 | |
PCT/US2002/041419 WO2003057148A2 (en) | 2001-12-27 | 2002-12-23 | Use of biomolecular targets in the treatment and visualization of tumors |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005523687A JP2005523687A (ja) | 2005-08-11 |
JP2005523687A5 true JP2005523687A5 (ja) | 2005-12-22 |
Family
ID=23346050
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003557507A Pending JP2005523687A (ja) | 2001-12-27 | 2002-12-23 | 腫瘍の処置及び可視化における生体分子標的の使用法 |
Country Status (6)
Country | Link |
---|---|
US (3) | US7368098B2 (ja) |
EP (1) | EP1465997A4 (ja) |
JP (1) | JP2005523687A (ja) |
AU (1) | AU2002360773A1 (ja) |
CA (1) | CA2469480A1 (ja) |
WO (1) | WO2003057148A2 (ja) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005073621A (ja) * | 2003-09-01 | 2005-03-24 | Japan Science & Technology Agency | 脳腫瘍マーカーと脳腫瘍の診断方法 |
US20050255045A1 (en) * | 2004-05-13 | 2005-11-17 | Woltering Eugene A | Surgical marking composition and method |
EP2290069A3 (en) * | 2004-05-28 | 2011-08-10 | Asuragen, Inc. | Methods and compositions involving microRNA |
WO2006020557A2 (en) * | 2004-08-10 | 2006-02-23 | Immusol, Inc. | Methods of using or identifying agents that inhibit cancer growth |
EP2808389A1 (en) | 2004-11-12 | 2014-12-03 | Asuragen, Inc. | Methods and compositions involving MIRNA and MIRNA inhibitor molecules |
WO2006051984A1 (ja) * | 2004-11-15 | 2006-05-18 | Kirin Beer Kabushiki Kaisha | 癌細胞の転移抑制方法およびそのために使用する医薬組成物 |
US9603941B2 (en) * | 2006-01-24 | 2017-03-28 | Minghui Chai | Method of preparing dendritic drugs |
EP2115138A2 (en) * | 2006-09-19 | 2009-11-11 | Asuragen, Inc. | Micrornas differentially expressed in pancreatic diseases and uses thereof |
WO2008036776A2 (en) * | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention |
DK2104737T3 (da) * | 2006-12-08 | 2013-05-27 | Asuragen Inc | Funktioner og formål for let-7 mikro-RNAer |
WO2008073915A2 (en) * | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Micrornas differentially expressed in leukemia and uses thereof |
AU2007333107A1 (en) * | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | miR-21 regulated genes and pathways as targets for therapeutic intervention |
US20090175827A1 (en) * | 2006-12-29 | 2009-07-09 | Byrom Mike W | miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
US20090232893A1 (en) * | 2007-05-22 | 2009-09-17 | Bader Andreas G | miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
US20090131354A1 (en) * | 2007-05-22 | 2009-05-21 | Bader Andreas G | miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
US20090227533A1 (en) * | 2007-06-08 | 2009-09-10 | Bader Andreas G | miR-34 Regulated Genes and Pathways as Targets for Therapeutic Intervention |
US8361714B2 (en) | 2007-09-14 | 2013-01-29 | Asuragen, Inc. | Micrornas differentially expressed in cervical cancer and uses thereof |
WO2009052386A1 (en) * | 2007-10-18 | 2009-04-23 | Asuragen, Inc. | Micrornas differentially expressed in lung diseases and uses thereof |
US8071562B2 (en) * | 2007-12-01 | 2011-12-06 | Mirna Therapeutics, Inc. | MiR-124 regulated genes and pathways as targets for therapeutic intervention |
WO2009086156A2 (en) * | 2007-12-21 | 2009-07-09 | Asuragen, Inc. | Mir-10 regulated genes and pathways as targets for therapeutic intervention |
WO2009100430A2 (en) * | 2008-02-08 | 2009-08-13 | Asuragen, Inc | miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS |
US20090233297A1 (en) * | 2008-03-06 | 2009-09-17 | Elizabeth Mambo | Microrna markers for recurrence of colorectal cancer |
WO2009154835A2 (en) * | 2008-03-26 | 2009-12-23 | Asuragen, Inc. | Compositions and methods related to mir-16 and therapy of prostate cancer |
US8258111B2 (en) | 2008-05-08 | 2012-09-04 | The Johns Hopkins University | Compositions and methods related to miRNA modulation of neovascularization or angiogenesis |
AU2009294085B2 (en) * | 2008-09-22 | 2013-08-22 | Nihon Medi-Physics Co., Ltd. | Device for creating database of alternative normal brain |
US20100074480A1 (en) * | 2008-09-22 | 2010-03-25 | University Of Washington | Device for generating alternative of normal brain database |
US20100179213A1 (en) * | 2008-11-11 | 2010-07-15 | Mirna Therapeutics, Inc. | Methods and Compositions Involving miRNAs In Cancer Stem Cells |
CN105969773A (zh) | 2011-02-03 | 2016-09-28 | 米尔纳医疗股份有限公司 | Mir-124的合成模拟物 |
WO2013040251A2 (en) | 2011-09-13 | 2013-03-21 | Asurgen, Inc. | Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease |
WO2015143074A1 (en) * | 2014-03-20 | 2015-09-24 | University Of Southern California | Brain cancer immunotherapy |
US20190119338A1 (en) * | 2016-03-31 | 2019-04-25 | Children's Medical Center Corporation | Compositions and methods for oligodendrocyte development |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030167485A1 (en) * | 1997-09-24 | 2003-09-04 | Garvan Institute Of Medical Research | Novel G protein-coupled receptor encoding gene and diagnostic uses therefor |
US6391311B1 (en) * | 1998-03-17 | 2002-05-21 | Genentech, Inc. | Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1 |
WO2000020590A2 (en) | 1998-10-06 | 2000-04-13 | Incyte Pharmaceuticals, Inc. | G-protein coupled receptor proteins |
EP1033404A1 (en) * | 1999-01-29 | 2000-09-06 | F. Hoffmann-La Roche Ag | New gene with down-regulated expression in metastatic human melanoma cells |
-
2002
- 2002-12-23 US US10/328,544 patent/US7368098B2/en not_active Expired - Lifetime
- 2002-12-23 CA CA002469480A patent/CA2469480A1/en not_active Abandoned
- 2002-12-23 WO PCT/US2002/041419 patent/WO2003057148A2/en not_active Application Discontinuation
- 2002-12-23 JP JP2003557507A patent/JP2005523687A/ja active Pending
- 2002-12-23 US US10/329,258 patent/US7014838B2/en not_active Expired - Lifetime
- 2002-12-23 AU AU2002360773A patent/AU2002360773A1/en not_active Abandoned
- 2002-12-23 EP EP02796055A patent/EP1465997A4/en not_active Withdrawn
-
2008
- 2008-03-10 US US12/045,448 patent/US20080226646A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005523687A5 (ja) | ||
Chen et al. | Integrin αvβ3-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy | |
Xie et al. | Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity | |
Petronzelli et al. | Therapeutic use of avidin is not hampered by antiavidin antibodies in humans | |
Grünwald et al. | Systemic image-guided liver cancer radiovirotherapy using dendrimer-coated adenovirus encoding the sodium iodide symporter as theranostic gene | |
Spenlé et al. | Tenascin-C: Exploitation and collateral damage in cancer management | |
Dai et al. | Modular peptide probe for pre/intra/postoperative therapeutic to reduce recurrence in ovarian cancer | |
Westberg et al. | Treatment efficacy and immune stimulation by AdCD40L gene therapy of spontaneous canine malignant melanoma | |
Li et al. | Expression of epidermal growth factor variant III (EGFRvIII) in pediatric diffuse intrinsic pontine gliomas | |
CN101555283B (zh) | 针对非功能性p2x7受体的抗体及其在癌症和其它病情的诊断和治疗中的用途 | |
Finn et al. | Importance of MUC1 and spontaneous mouse tumor models for understanding the immunobiology of human adenocarcinomas | |
Marin et al. | Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma | |
Vandergrift et al. | Convection-enhanced delivery of immunotoxins and radioisotopes for treatment of malignant gliomas | |
Mitran et al. | Trastuzumab cotreatment improves survival of mice with PC‐3 prostate cancer xenografts treated with the GRPR antagonist 177Lu‐DOTAGA‐PEG2‐RM26 | |
Spitzweg et al. | The sodium iodide symporter (NIS): novel applications for radionuclide imaging and treatment | |
Shih et al. | 111In-cetuximab as a diagnostic agent by accessible epidermal growth factor (EGF) receptor targeting in human metastatic colorectal carcinoma | |
Fujiwara et al. | 90Y-labeled anti-ROBO1 monoclonal antibody exhibits antitumor activity against small cell lung cancer xenografts | |
You et al. | Molecular magnetic resonance probe targeting VEGF165: preparation and in vitro and in vivo evaluation | |
Ehlerding et al. | 86/90Y-based theranostics targeting angiogenesis in a murine breast cancer model | |
Lee et al. | A PSMA-targeted bispecific antibody for prostate cancer driven by a small-molecule targeting ligand | |
Notni et al. | In vivo imaging of early stages of rheumatoid arthritis by α5β1-integrin-targeted positron emission tomography | |
JP2001513111A (ja) | 腫瘍付随血管(tumor−associated blood vessels)上の血管透過因子の複数のエピトープに結合する同時インビボイムノコンジュゲート | |
Tan et al. | Combination of low‐dose cisplatin and recombinant xenogeneic endoglin as a vaccine induces synergistic antitumor activities | |
Niwa et al. | Novel immunoliposome technology for enhancing the activity of the agonistic antibody against the tumor necrosis factor receptor superfamily | |
Heo et al. | Folate receptor α-targeted 89Zr-M9346A immuno-PET for image-guided intervention with mirvetuximab soravtansine in triple-negative breast cancer |